Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johnathan Man

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
JNCI Cancer Spectrum|June 4, 2021
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC TrialsJohnathan Man, Jared Millican, Arthur Mulvey, et al.
Asia-Pacific Journal of Clinical Oncology|January 20, 2018
Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysisJohnathan Man, Georgia Ritchie, Matthew Links, et al.
JAMA Oncology|February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysisGeorgia Ritchie, Harry Gasper, Johnathan Man, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
JCO Precision Oncology|February 17, 2022
Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-AnalysisDoah Cho, Felicia T Roncolato, Johnathan Man, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
NPJ Primary Care Respiratory Medicine|February 10, 2019
Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort studyStuart Purdie, Nicola Creighton, Kahren Maree White, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
JNCI Cancer Spectrum|June 4, 2021
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC TrialsJohnathan Man, Jared Millican, Arthur Mulvey, et al.
Asia-Pacific Journal of Clinical Oncology|January 20, 2018
Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysisJohnathan Man, Georgia Ritchie, Matthew Links, et al.
JAMA Oncology|February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysisGeorgia Ritchie, Harry Gasper, Johnathan Man, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
JCO Precision Oncology|February 17, 2022
Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-AnalysisDoah Cho, Felicia T Roncolato, Johnathan Man, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
NPJ Primary Care Respiratory Medicine|February 10, 2019
Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort studyStuart Purdie, Nicola Creighton, Kahren Maree White, et al.
Pageof 1